Didanosine
- Generic Name
- Didanosine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N4O3
- CAS Number
- 69655-05-6
- Unique Ingredient Identifier
- K3GDH6OH08
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.
- Indication
For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study to Compare Two Different Anti-HIV Drug Regimens
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 120
- Registration Number
- NCT00000924
- Locations
- 🇺🇸
Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Chicago Children's Memorial Hosp, Chicago, Illinois, United States
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 399
- Registration Number
- NCT00000916
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Weiss Memorial Hosp., Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 150
- Registration Number
- NCT00000939
- Locations
- 🇺🇸
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States
🇺🇸San Mateo AIDS Program / Stanford Univ, Stanford, California, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 20
- Registration Number
- NCT00000833
- Locations
- 🇺🇸
Schneider Children's Hosp, New Hyde Park, New York, United States
🇺🇸Children's Hosp of Boston, Boston, Massachusetts, United States
🇺🇸Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 471
- Registration Number
- NCT00000803
- Locations
- 🇺🇸
Bmc Actg Crs, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 105
- Registration Number
- NCT00001057
- Locations
- 🇺🇸
Univ of Nebraska Med Ctr, Omaha, Nebraska, United States
🇺🇸Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 42
- Registration Number
- NCT00000710
- Locations
- 🇺🇸
SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States
A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2100
- Registration Number
- NCT00000625
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States
🇺🇸Ucsd, Avrc Crs, San Diego, California, United States
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 32
- Registration Number
- NCT00001024
- Locations
- 🇺🇸
Univ of Illinois, Chicago, Illinois, United States
🇺🇸Univ of Maryland at Baltimore, Baltimore, Maryland, United States
🇺🇸Duke Univ Med Ctr, Durham, North Carolina, United States
A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1200
- Registration Number
- NCT00001022
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸AIDS Research Alliance - Chicago, Chicago, Illinois, United States
🇺🇸Community Consortium of San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.